abramson_sc13d-lorusno9.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under The Securities Exchange Act of 1934

(Amendment No. 9)*

Lorus Therapeutics Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

544192107

(CUSIP Number)

Herbert Abramson

22 St. Clair Avenue East, 18th Floor

Toronto, Ontario, Canada

M4T 2S3

(416) 361-1498

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 1, 2010

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. 544192107

1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON Technifund Inc. I.R.S. IDENTIFICATION NO. - Not Applicable

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) x

3	SEC USE ONLY

4	SOURCE OF FUNDS WC

5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o

6	CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER 1,303,468
	8	SHARED VOTING POWER 0
	9	SOLE DISPOSITIVE POWER 1,303,468
	10	SHARED DISPOSITIVE POWER 0

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,303,468*

12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.7%*

14	TYPE OF REPORTING PERSON HC

*See Item 5

CUSIP NO. 544192107

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Herbert Abramson I.R.S. IDENTIFICATION NO. - Not Applicable

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) x

3	SEC USE ONLY

4	SOURCE OF FUNDS PF

5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) o

6	CITIZENSHIP OR PLACE OF ORGANIZATION Canadian

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER 10,336,402
	8	SHARED VOTING POWER 0
	9	SOLE DISPOSITIVE POWER 10,336,402
	10	SHARED DISPOSITIVE POWER 0

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,336,402*

12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 52.8%*

14	TYPE OF REPORTING PERSON IN

This Amendment No. 9 (the “Amendment”) with respect to the Common Stock of Lorus Therapeutics Inc. (the “Issuer”) amends and supplements the Schedule 13D, as amended (the “Schedule 13D”), which was originally filed on July 23, 2007. Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Schedule 13D. The Schedule 13D is hereby amended and supplemented as follows:

Item 3. Source and Amount of Funds or Other Consideration

On November 29, 2010, Abramson acquired 1,410,000 common shares at CDN$1.05 per share. The shares were acquired from treasury in connection with a private placement by the Issuer.

The purchase price of the Common Stock reported in this Schedule 13D was CDN$16,654,641. The Common Stock to which this Schedule 13D relates was purchased using working capital, in respect of shares purchased by Technifund, and personal funds in respect of shares purchased by Abramson.

Item 5. Interest in Securities of the Issuer

(a) As of the close of business on November 29, 2010, the Reporting Persons’ beneficial ownership of Common Stock was 10,336,402 shares. Of this amount, 9,032,934 shares of Common Stock (including warrants exercisable into 3,557,725 shares of Common Stock and options exercisable into 14,999 shares of Common Stock) were held by Abramson directly and 1,303,468 shares of Common Stock (including warrants exercisable into 325,867 shares of Common Stock) were held by Technifund directly.

(b) The responses of the Reporting Persons to Items 7 through 13 on the cover pages are incorporated herein by reference. All responses reflect the beneficial ownership as of the close of business on November 29, 2010. Abramson exercises sole voting and dispositive power over shares held by him and Technifund. Technifund exercises sole voting and dispositive power over the shares held by it.

(c) The following are all transactions in the Common Stock beneficially owned by the Reporting Persons that were effected during the past sixty days:

(d) Other than the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock reported in this Schedule 13D.

Item 7. Material to be Filed as Exhibits

Exhibit B Joint Filing Agreement, dated July 31, 2007, by and between Abramson and Technifund*

* Previously filed with the Schedule 13D on July 23, 2007.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

December 1, 2010	By:	/s/ Herbert Abramson
		Herbert Abramson

	TECHNIFUND INC.

	By:	/s/ Herbert Abramson
		Name: Herbert Abramson
		Title: President